The Efficacy of Lovastatin in Lowering Cholesterol in African Americans with Primary Hypercholesterolemia-Reference-Cited by-同舟云学术

The Efficacy of Lovastatin in Lowering Cholesterol in African Americans with Primary Hypercholesterolemia

Published:1997-04 Issue:4 Volume:102 Page:387-391
ISSN:0002-9343
Container-title:The American Journal of Medicine
language:en
Short-container-title:The American Journal of Medicine

Author:

Fong Ronald L,Ward Harry J

Publisher

Elsevier BV

Subject

General Medicine

Reference32 articles.

1. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms;Levine;NEJM.,1995

2. Serum total cholesterol and long-term coronary heart disease mortality in different countries. Twenty-five year follow-up of the Seven Countries Study;Verschuren;JAMA.,1995

3. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction;Stampfer;NEJM.,1991

4. HMG-CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin;Maher;Q J Med.,1990

5. Simvastatin versus pravastatin: efficacy and tolerability in patients with primary hypercholesterolemia;Malini;Clin Ther.,1991

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiac rehabilitation in African Americans: Evidence for poorer outcomes compared with whites, especially in women and diabetic participants;American Heart Journal;2015-01

2. A Retrospective Cohort Study of the Potency of lipid-lowering therapy and Race-gender Differences in LDL cholesterol control;BMC Cardiovascular Disorders;2011-09-30

3. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: The Antihypertensive and Lipid Lowering to Prevent Heart Attack Trial (ALLHAT-LLT);American Heart Journal;2009-12

4. Predictors, Barriers, and Facilitators of Lipid-Lowering Medication Use Among African Americans in a Primary Care Clinic;Journal of the National Medical Association;2009-09

5. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present;Pharmacoepidemiology and Drug Safety;2007